Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

REFERENCES

1. 1.↵
   1. Klippel JH

   1. Pisetsky DS

   . Systemic lupus erythematosus. A. Epidemiology, pathology, and pathogenesis. In: Klippel JH, ed. Primer on the rheumatic diseases. 12th ed. Atlanta, GA: Arthritis Foundation; 2001:329–35.
2. 2.↵
   1. Bernatsky S,
   2. Boivin JF,
   3. Joseph L,
   4. Rajan R,
   5. Zoma A,
   6. Manzi S,
   7. et al.

   An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481–90.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Bernatsky S,
   2. Joseph L,
   3. Boivin JF,
   4. Gordon C,
   5. Urowitz M,
   6. Gladman D,
   7. et al.

   The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 2008;67:74–9.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Cervera R,
   2. Khamashta MA,
   3. Font J,
   4. Sebastiani GD,
   5. Gil A,
   6. Lavilla P,
   7. et al.

   Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003; 82:299–308.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Goldblatt F,
   2. Chambers S,
   3. Rahman A,
   4. Isenberg DA

   . Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus 2009;18:682–9.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Roman MJ,
   2. Shanker BA,
   3. Davis A,
   4. Lockshin MD,
   5. Sammaritano L,
   6. Simantov R,
   7. et al.

   Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399–406.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Petri M,
   2. Purvey S,
   3. Fang H,
   4. Magder LS

   . Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012;64:4021–8.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Thamer M,
   2. Hernán MA,
   3. Zhang Y,
   4. Cotter D,
   5. Petri M

   . Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560–4.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Zonana-Nacach A,
   2. Barr SG,
   3. Magder LS,
   4. Petri M

   . Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801–8.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Gladman DD,
    2. Urowitz MD,
    3. Rahman P,
    4. Ibañez D,
    5. Tam LS

    . Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955–9.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Cheema GS,
    2. Roschke V,
    3. Hilbert DM,
    4. Stohl W

    . Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313–9.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Groom J,
    2. Kalled SL,
    3. Cutler AH,
    4. Olson C,
    5. Woodcock SA,
    6. Schneider P,
    7. et al.

    Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome. J Clin Invest 2002;109:59–68.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Mariette X,
    2. Roux S,
    3. Zhang J,
    4. Bengoufa D,
    5. Lavie F,
    6. Zhou T,
    7. et al.

    The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis 2003;62:168–71.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Zhang J,
    2. Roschke V,
    3. Baker KP,
    4. Wang Z,
    5. Alarcón GS,
    6. Fessler BJ,
    7. et al.

    Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6–10.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Petri M,
    2. Stohl W,
    3. Chatham W,
    4. McCune WJ,
    5. Chevrier M,
    6. Ryel J,
    7. et al.

    Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008;58:2453–9.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Hahn BH,
    2. McMahon MA,
    3. Wilkinson A,
    4. Wallace WD,
    5. Daikh DI,
    6. Fitzgerald JD,
    7. et al.

    American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797–808.

    OpenUrlCrossRef
17. 17.↵
    1. Petri M,
    2. Singh S,
    3. Tesfasyone H,
    4. Malik A

    . Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheumatol 2009;36:2476–80.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Schmajuk G,
    2. Yazdany J

    . Drug monitoring in systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 2011;40:559–75.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Schur PH,
    2. Sandson J

    . Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968;278:533–8.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. ter Borg EJ,
    2. Horst G,
    3. Hummel EJ,
    4. Limburg PC,
    5. Kallenberg CG

    . Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990;33:634–43.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Tseng CE,
    2. Buyon JP,
    3. Kim M,
    4. Belmont HM,
    5. Mackay M,
    6. Diamond B,
    7. et al.

    The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:3623–32.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Baker KP,
    2. Edwards BM,
    3. Main SH,
    4. Choi GH,
    5. Wager RE,
    6. Halpern WG,
    7. et al.

    Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253–65.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Halpern WG,
    2. Lappin P,
    3. Zanardi T,
    4. Cai W,
    5. Corcoran M,
    6. Zhong J,
    7. et al.

    Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006;91:586–99.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Wallace DJ,
    2. Stohl W,
    3. Furie RA,
    4. Lisse JR,
    5. McKay JD,
    6. Merrill JT,
    7. et al.

    A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168–78.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Furie R,
    2. Petri M,
    3. Zamani O,
    4. Cervera R,
    5. Wallace DJ,
    6. Tegzová D,
    7. et al.

    A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Navarra SV,
    2. Guzman RM,
    3. Gallacher AE,
    4. Hall S,
    5. Levy RA,
    6. Jimenez RE,
    7. et al.

    Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Furie RA,
    2. Petri MA,
    3. Wallace DJ,
    4. Ginzler EM,
    5. Merrill JT,
    6. Stohl W,
    7. et al.

    Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143–51.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Stohl W,
    2. Hiepe F,
    3. Latinis KM,
    4. Thomas M,
    5. Scheinberg MA,
    6. Clarke A,
    7. et al.

    Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64:2328–37.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Merrill JT,
    2. Ginzler EM,
    3. Wallace DJ,
    4. McKay JD,
    5. Lisse JR,
    6. Aranow C,
    7. et al; and
    8. LBSL02/99 Study Group

    . Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:3364–73.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Petri M,
    2. Buyon J,
    3. Kim M

    . Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685–91.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Petri M,
    2. Kim MY,
    3. Kalunian KC,
    4. Grossman J,
    5. Hahn BH,
    6. Sammaritano LR,
    7. et al.

    Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550–8.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Gordon C,
    2. Sutcliffe N,
    3. Skan J,
    4. Stoll T,
    5. Isenberg DA

    . Definition and treatment of lupus flares measured by the BILAG index. Rheumatology 2003;42:1372–9.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    1. Hay EM,
    2. Bacon PA,
    3. Gordon C,
    4. Isenberg DA,
    5. Maddison P,
    6. Snaith ML,
    7. et al.

    The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. QJ Med 1993;86:447–58.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Isenberg DA,
    2. Gordon C; and
    3. BILAG Group

    . British Isles Lupus Assessment Group. From BILAG to BLIPS: disease activity assessment in lupus past, present and future. Lupus 2000;9:651–4.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Buyon JP,
    2. Petri MA,
    3. Kim MY,
    4. Kalunian KC,
    5. Grossman J,
    6. Hahn BH,
    7. et al.

    The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142:953–62.

    OpenUrlCrossRefPubMed
36. 36.↵
    1. National Institute of Allergy and Infectious Diseases

    . Toxicity Tables. Division of Microbiology and Infectious Diseases, 2001. [Internet. Accessed Sept 10, 2013]. Available from: http://www.niaid.nih.gov/labsandresources/resources/dmidclinrsrch/pages/toxtables.aspx
37. 37.↵
    1. Bernatsky S,
    2. Boivin JF,
    3. Joseph L,
    4. Manzi S,
    5. Ginzler E,
    6. Gladman DD,
    7. et al.

    Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550–7.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Ippolito A,
    2. Petri M

    . An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 2008;26 Suppl 51:S72–9.

    OpenUrlPubMed
39. 39.↵
    1. Karim MY,
    2. Pisoni CN,
    3. Khamashta MA

    . Update on immunotherapy for systemic lupus erythematosus – What’s hot and what’s not! Rheumatology 2009;48:332–41.

    OpenUrlAbstract/FREE Full Text
40. 40.↵
    1. Lateef A,
    2. Petri M

    . Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010;22:504–9.

    OpenUrlCrossRefPubMed